Samsung Biologics scores big at 2026 CDMO Leadership Awards

The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers

Bavarian Nordic seeks EMA nod for Mpox vaccine in children aged 2–11

The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN

GSK seeks European nod for promising Hepatitis B therapy

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial

Roche launches groundbreaking multiplex test to boost blood safety

The new assay consolidates screening for four major viral threats into a single workflow

Teva hits major biosimilar milestones with FDA nod and regulatory filings

The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Allergan Aesthetics showcases breakthroughs at AAD 2026

Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments

Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy

The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract

Lupin receives FDA’s tentative approval for Sugammadex injection

Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery